- Home
- KLIC vs ETNB Comparison
KLIC vs ETNB Comparison
Compare KLIC & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLIC
- ETNB
- Stock Information
- Founded
- KLIC 1951
- ETNB 2018
- Country
- KLIC United States
- ETNB United States
- Employees
- KLIC N/A
- ETNB N/A
- Industry
- KLIC Semiconductors
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- KLIC Technology
- ETNB Health Care
- Exchange
- KLIC Nasdaq
- ETNB Nasdaq
- Market Cap
- KLIC 1.7B
- ETNB 1.5B
- IPO Year
- KLIC N/A
- ETNB 2019
- Fundamental
- Price
- KLIC $33.46
- ETNB $10.08
- Analyst Decision
- KLIC Strong Buy
- ETNB Strong Buy
- Analyst Count
- KLIC 4
- ETNB 8
- Target Price
- KLIC $48.00
- ETNB $26.43
- AVG Volume (30 Days)
- KLIC 647.9K
- ETNB 2.2M
- Earning Date
- KLIC 08-06-2025
- ETNB 08-04-2025
- Dividend Yield
- KLIC 2.45%
- ETNB N/A
- EPS Growth
- KLIC N/A
- ETNB N/A
- EPS
- KLIC 0.40
- ETNB N/A
- Revenue
- KLIC $691,079,000.00
- ETNB N/A
- Revenue This Year
- KLIC N/A
- ETNB N/A
- Revenue Next Year
- KLIC $14.33
- ETNB N/A
- P/E Ratio
- KLIC $84.19
- ETNB N/A
- Revenue Growth
- KLIC N/A
- ETNB N/A
- 52 Week Low
- KLIC $26.63
- ETNB $4.16
- 52 Week High
- KLIC $53.71
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- KLIC 49.44
- ETNB 57.88
- Support Level
- KLIC $33.82
- ETNB $9.66
- Resistance Level
- KLIC $35.64
- ETNB $10.58
- Average True Range (ATR)
- KLIC 1.03
- ETNB 0.55
- MACD
- KLIC 0.01
- ETNB -0.09
- Stochastic Oscillator
- KLIC 40.10
- ETNB 58.39
About KLIC Kulicke and Soffa Industries Inc.
Kulicke & Soffa Industries Inc is a United States-based company that is principally engaged in designing, manufacturing, and selling capital equipment and expendable tools that are used for assembling semiconductor devices. The company has four reportable segments which includes Ball Bonding Equipment, Wedge Bonding Equipment, Advanced Solutions, and Aftermarket Products and Services. Its Ball Bonding Equipment segment which generates the majority of the revenue for the company includes results of the company from the design, development, manufacture and sale of ball bonding equipment and wafer level bonding equipment. The majority of its customers are located in the Asia-pacific region.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).